Premium
The role of combining immunotherapy with primary (Chemo)radiotherapy in curative treatment settings of the head and neck cancer
Author(s) -
Dua Divyanshu,
Kelly Charles,
Kovarik Josef,
Iqbal Muhammad Shahid
Publication year - 2022
Publication title -
asia‐pacific journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.73
H-Index - 29
eISSN - 1743-7563
pISSN - 1743-7555
DOI - 10.1111/ajco.13583
Subject(s) - medicine , head and neck cancer , radiation therapy , immunotherapy , clinical trial , head and neck , oncology , adjuvant , disease , cancer , surgery
The introduction of immunotherapy into the radical management of head and neck cancer (HNC) is a fast moving phenomenon, which is constantly developing. Although now established in the management of recurrent and metastatic disease in HNC, its use in radical treatment is being investigated in a whole spectrum of clinical trials looking at which immune altering agents give the best results, which can be added safely to radiotherapy, chemotherapy, and chemoradiotherapy for greatest efficiency and when the most appropriate time to add these agents is in the neoadjuvant, concurrent on adjuvant settings. These multiple questions produce a complex matrix for HNC investigators and this article brings together the existing evidence and contemporary trials going on with immunotherapy in HNC, giving an up to date snapshot of present investigations and near future directions for further research.